Business
Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases
Broad multiyear alliance with Columbia University Irving Medical Center researchers to focus on development of potential medicines using genetic based
About this update from Ovid Therapeutics Inc.
[{"type":"text","content":"Broad multiyear alliance with Columbia University Irving Medical Center researchers to focus on development of potential medicines using genetic based therapies and create a therapeutic platform for a range of rare neurological conditionsOvid to collaborate with renowned clinical and molecular geneticist expert, Wendy K. Chung, M.D., Ph.D.Collaboration provides Ovid with the opportunity to expand future drug development portfolio NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced a strategic research collaboration with Columbia University Irving Medical Center researchers (“Columbia”) to advance genetic based therapies for a range of rare neurological conditions, complementary to Ovid’s current pipeline. This collaboration provides Ovid with the potential to expand its future drug development portfolio and impact individuals living with rare genetic neurological conditions.\n Under this research and translational development alliance, Columbia will align its expertise in rare disease genetics and deep clinical understanding of rare neurological diseases with Ovid’s discovery, translational, and clinical development expertise in neurodevelopmental disorders and rare epilepsies. Ovid will work closely with Wendy K. Chung, M.D., Ph.D., the Chief of Clinical Genetics, and leader of the Precision Medicine Resource in the Irving Institute at Columbia University Irving Medical Center. Dr. Chung is a recognized genetics leader with over 20 years of experience in human genetic research of monogenic and complex traits, mapping and cloning genes in humans, and describing the clinical characteristics and natural history of novel genetic conditions. A 2019 National Organization for Rare Disorders (NORD) Rare Impact Award Honoree, Dr. Chung is also a leader and advocate within the rare disease patient community. Under the collaboration, Ovid will work together with Columbia scientists to identify molecular targets for developing genetic/molecular therapeutic approaches for rare neurological conditions such as KIF1A-associated neurological disorder (KAND) and other rare conditions. “Ovid has made significant progress in all its late stage clinical programs. We are exci...